Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, June 16, 2017
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop
Tuesday, June 6, 2017
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting
Thursday, May 18, 2017
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology
Saturday, April 29, 2017
Nanobiotix: 2016 Annual Results
Tuesday, April 4, 2017
Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology
Friday, March 24, 2017
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma
Tuesday, March 7, 2017
Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017
Tuesday, February 7, 2017
Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer
Wednesday, February 1, 2017
NANOBIOTIX: 2016 Review and 2017 Anticipated Milestones
Thursday, December 15, 2016
Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: